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Systemic gene delivery is a complicated and multistep process that confronts numerous 
biological barriers. It remains a formidable challenge to exploit a single gene carrier with 
multiple features to combat all obstacles collectively. Herein, we demonstrate a multi-
responsive "turn-on" polyelectrolyte complex (DNA/OEI-SSx/HA-SS-COOH, DSS) delivery 
system with a sequential self-assembly of disulfide-conjugated oligoethylenimine (OEI-SSx) 
and disulfide bond-modified hyaluronic acid envelope (HA-SS-COOH) that can combat 
multiple biological barriers collectively when administered intravenously. DSS is designed to 
effectively accumulate at the tumor tissue and to be internalized into tumor cells by 
recognizing CD44. The multi-responsive "turn-on" DSS can respond to the alterations of 
hyaluronidases and glutathione at both the tumor site and at the intracellular milieu. 
Sequential degradation and detachment of the HA-SS-COOH envelope followed by the 
dissociation of the OEI-SSx/DNA inner core contributes to the activation of the endosomal 
escape and gene release functions, thus greatly enhancing nuclear gene delivery. A systematic 
investigation of DSS has revealed that the tumor accumulation ability, internalization and 
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endosome escape of the DSS nanocarriers, DNA unpacking and nuclear transportation are all 
remarkably improved by the multi-responsive "turn-on" design resulting in highly efficient 
gene transfection in vitro and in vivo. 
1. Introduction 
The imperative issue to achieve satisfactory cancer gene therapy ultimately lies in the ability 
of carriers to deliver exogenous therapeutic genes to target cells.[1] Because systemic gene 
delivery is a complicated and multistep process, gene carriers have to overcome numerous 
biological barriers[2] that hinder the effective delivery of DNA to target locations, including (i) 
gene condensation while avoiding polyanion-mediated dissociation and DNase degradation 
during blood circulation, (ii) extravasation through the leaky tumor vasculature (passive 
targeting) and accumulation in the interstitial space where carriers are retained due to the lack 
of lymphatic clearance (enhanced permeability and retention effect)[3], (iii)  internalization 
into target cells to reduce toxic side-effects, (iv) endosomal escape, (v) dissociation of gene 
carriers and unpacking of the DNA, and (vi) delivery into the nucleus for transfection. 
Although great efforts have been devoted to develop various gene carriers for overcoming one 
or several biological barriers, it remains a formidable challenge to exploit a single 
multifunctional gene carrier to combat the majority of obstacles simultaneously to fulfill 
satisfactory gene transfection efficiency with minimal toxicity.[4] 
 
It is encouraging to note that a multitude of cationic lipids and polymers,[5] such as 
polyethylenimine (PEI), polyamidoamine (PAMAM) and polylysine (PLL), have been 
extensively tailored to fight against hurdles in the gene delivery process. One of the highly 
promising strategies is to design stimulus-responsive nanocarriers for overcoming the stability 
dilemma and reducing toxicity. Redox-sensitive degradable polycations[6] allow both 
condensation and delivery of nucleic acids. This type of polycation is designed to remain 
stable under physiological conditions, whereas dissociation takes place rapidly and selectively 
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upon intracellular delivery. This design also has been demonstrated to reduce toxicity while 
retaining the gene transfer ability. Actually, most polycation-based nanocarriers can self-
assemble from electrostatic interactions between cationic polymers and anionic nucleic acids 
and feature a positively charged surface and can bind to a cell membrane having a negative 
charge to achieve pinocytosis or endocytosis. This type of pinocytosis or endocytosis is 
always considered to be non-specific adsorption regardless of the cell type[7] and generally 
leads to non-specificity in biodistribution and safety problems.  
 
Varieties in comprehensive design criteria have recently been used to overcome the above-
mentioned limitations of polycation-based nanocarriers.[5, 8] One attractive strategy proposes 
the use of a shelter with functional groups that can connect to the preformed inner cationic 
core. The most common shielding agents are hydrophilic macromolecules — PEG,[8a, 8c, 9] 
polysaccharides,[10] polyaspartamide and polyglutamic acid derivatives.[8b, 8c, 11] Polymer-lipid 
hybrid systems[12] (also known as MEND[13] and LPD[14]) are also advanced approaches. On 
the one hand, these approaches can alter the surface properties of polycation-based 
nanocarriers by shielding their positive surface charges. This approach would be beneficial in 
eliminating non-specific interactions with anionic serum proteins and avoiding nanocarrier 
dissociations due to competitive binding of heparin during blood circulation. However, 
conversely, shielding the polycation-based nanocarriers with neutral or anionic polymers 
reduces the internalization efficiency and the endosomal escape ability. 
 
Therefore, it is urgent to develop a gene delivery system with numerous characteristics 
integrated and optimized to fight against multiple impediments simultaneously during gene 
delivery. Herein, taking the transfection barriers involved in non-viral gene delivery into 
account, we demonstrate multi-responsive "turn-on" polyelectrolyte complex (DNA/OEI-
SSx/HA-SS-COOH, DSS) as multifunctional gene carriers with sequential self-assembly of 
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disulfide-conjugated oligoethylenimine (OEI-SSx) and disulfide bond-modified hyaluronic 
acid envelopes (HA-SS-COOH) (Scheme 1). CD44 is a major cell surface receptor for HA 
and is overexpressed in various tumors. The N-terminal link module homology domain of 
CD44 is responsible for binding to HA.[15] Because HA has a high affinity for the cancer 
marker CD44, HA-SS-COOH is utilized not only as a targeting moiety but also for a 
detachable envelope to DNA/OEI-SSx inner polyplexes via electrostatic forces. DSS are 
designed to effectively accumulate and become internalized in tumors, which overexpress the 
CD44 receptor, and then to activate endosomal escape and gene release functions resulting in 
highly efficient site-specific gene transfection in vitro and in vivo. The multi-responsive "turn-
on" DSS nanocarriers can sense the tumor biological milieu and respond to the alterations in 
hyaluronidases or glutathione (GSH) at both the tumor site and the intracellular milieu. The 
HA-SS-COOH envelope is prone to degradation by hyaluronidases. The levels of 
hyaluronidases are always high in several types of carcinomas including liver cancer,[16] 
colorectal carcinoma[17] and breast cancer[18]. Hyaluronidases appear not only on the exofacial 
surface but also inside cells. Accordingly, internalization of DSS is a crucial step for envelope 
degradation. After binding to the CD44 receptor, hyaluronidase-2 outside cells with a broader 
pH[19] optimum initiates extracellular degradation of HA-SS-COOH into fragments of ~20 
kDa. After forming caveolae, transferring to endosomes and finally fusing with lysosomes, 
the envelope fragments are further degraded into oligosaccharides by hyaluronidase-1 inside 
cells[20]. Furthermore, the disulfide bonds in the HA-SS-COOH envelope and OEI-SSx/DNA 
inner core readily cleave due to the high concentration of GSH (1-10 mM)[21] in the cytosol 
leading to the dissociation of the nanocarriers, activation of endosomal escape and the release 
of DNA on-demand. In this study, DSS nanocarriers were systematically investigated in 
comparison with control nanocarriers (insensitive golden standard DNA/PEI (DP), non-
enveloping DNA/OEI-SSx (DS) and stable envelope DNA/OEI-SSx/HA (DSH)). The tumor 
accumulation ability, internalization and endosome escape of the DSS nanocarriers, DNA 
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unpacking and nuclear transportation were all remarkably improved by the multi-responsive 
"turn-on" design resulting in enormously efficient gene transfection in vitro and in vivo.  
Acronyms 
OEI-SSx Disulfide cross-linked branch OEI800 
HA-SS-COOH HA with 30 mol% disulfide modification between pendent carboxyl groups and 
backbone 
DS DNA/OEI-SSx polyplexes 
DSH DNA/OEI-SSx/HA polyplexes 
DSS DNA/OEI-SSx/HA-SS-COOH polyplexes 
DP DNA/PEI polyplexes 
DPH DNA/PEI/HA polyplexes 
DPS DNA/PEI/HA-SS-COOH polyplexes  
 
2. Results 
2.1. Design, Synthesis and Characterization of the Nanocarriers 
The multi-responsive “turn-on” DNA/OEI-SSx/HA-SS-COOH (DSS) nanocarriers were 
synthesized (Figure S1, Supporting Information) consisting of a bioreducible DNA/OEI-SSx 
polyplex core and a hyaluronidase and GSH dual-sensitive HA-SS-COOH envelope. Its 
reductive degradation behavior was confirmed using GPC analysis. The molecular weight 
distribution of the OEI-SSx is narrow and comparable to PEI 25 kDa before treatment but 
degraded significantly after incubation with 10 mM dithiothreitol (DTT) for half an hour with  
a characteristic molecular weight close to OEI 800 Da (Figure S2A, Supporting Information). 
The molecular structure of the HA-SS-COOH envelope with 30 mol% disulfide linkages was 
also confirmed by 1HNMR spectra (Figure S2B, Supporting Information). DNA was 
complexed with OEI-SSx in HBG buffer resulting in DNA/OEI-SSx polyplexes. A detachable 
and targeted outer HA-SS-COOH envelope was then added onto the polyplexes surface to 
generate DNA/OEI-SSx/HA-SS-COOH nanocarriers in a core-shell structure (Scheme 1). 
The HA-SS-COOH envelope is expected to degrade stepwise by hyaluronidases at both the 
tumor site and in the intracellular milieu and further respond to high concentration GSH by 
completely detaching the envelope and disassembling the DNA-encapsulating core. These 
multi-responsive features would be beneficial for facilitating endosomal escape and on-
demand unpacking of the loaded genes for nuclear delivery. 
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Scheme 1. (A) Schematic fabrication process of the multi-responsive “turn-on” DSS 
nanocarriers. (B) Schematic representation of DSS-mediated gene delivery.  
 
The size and zeta potential variation of DSS under reductive conditions (10 mM DTT) were 
measured (Figure 1A and B). The particle sizes of the DSS (OEI-SSx/DNA = 10; w/w) 
ranged from 110 to 196 nm, and the zeta potential was from +27.0 mV to +5.8 mV depending 
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on the HA-SS-COOH/DNA and OEI-SSx/DNA ratios. When treated with 10 mM DTT, the 
size of DSS sharply increased to approximately 1 micron and the zeta potential decreased, 
indicating the aggregation of DSS nanocarriers. The particle sizes of the DSS (OEI-SSx/DNA 
= 10, HA-SS-COOH/DNA = 2; w/w) dispersed in acetate buffer without hyaluronidases 
presented no significant changes during the measurement process, suggesting a high level of 
stability. When incubated with hyaluronidase at concentrations of 60 and 120 units mL-1 for 
80 min, however, the size sharply increased to 712.8 ± 45.6 nm and 868.1 ± 52.4 nm, 
implying the degradation of the HA-SS-COOH envelope (Figure 1C).  TEM images showed 
that DSH (OEI-SSx/DNA = 10, HA/DNA = 1; w/w) and DSS (OEI-SSx/DNA = 10, HA-SS-
COOH/DNA = 2; w/w) had a similar uniform spherical morphology of approximately 120 nm 
(Figure 1D). When treated with 120 units mL-1 hyaluronidase for 30 min, the morphology of 
DSS became irregular, but the size did not increase significantly in comparison with DLS 
measurement. The discrepancy between TEM and DLS is partly because DLS measures a 
hydrodynamic size rather than a physical size, and DLS is biased towards larger size fractions. 
When further treated with 10 mM DTT, as expected, DSS exhibited an irregular and 
aggregated morphology. 
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Figure 1. (A) Particle sizes and (B) zeta potential of the indicated gene carriers (DS, DSH and 
DSS were prepared at OEI-SSx to DNA weight ratio of 10) in the absence or presence of 10 
mM DTT. (C) Varies in size of DSS (OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 2; w/w) 
incubated with different concentrations of hyaluronidase for different times. (n=6, ** p < 0.05 
by one-way ANOVA, followed by Tukey's post-hoc test). (D) TEM images of (a) DSH (OEI-
SSx/DNA = 10, HA/DNA = 1; w/w), (b) DSS (OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 2; 
w/w), (c) DSS treated with 120 units/mL hyaluronidase, and (d) DSS treated with 
hyaluronidase (120 units/mL) and DTT (10 mM). 
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Figure 2. Cell viability assays of various gene carriers with different envelope/DNA ratios in 
(A) B16F10, (B) HepG2 and (C) NIH3T3 cells for 24 h of incubation (n = 6, * p < 0.05 by 
two-way ANOVA, followed by Tukey's post-hoc test). (DNA concentration is 2 μg/mL. DP: 
PEI/DNA = 1.33; DS: OEI-SSx/DNA = 10; DSS: OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 
0.2 ~ 5; DSH: OEI-SSx/DNA = 10, HA/DNA = 0.2 ~ 5; w/w)  
 
 
2.2. Cytotoxicity Assessment 
Concentration-dependent cytotoxicity of PEI25kDa, OEI800Da and OEI-SSx was investigated in 
HepG2 cells. As shown in Figure S3, less cytotoxicity was found for OEI-SSx compared with 
PEI at the same concentration.  To further evaluate the anionic coating effect of HA-SS-
COOH on OEI-SSx/DNA polyplexes, the cytotoxicity of the various gene carriers at working 
concentrations was assessed in B16F10, HepG2 and NIH3T3 cells. The cell viability of DP-
treated B16F10, HepG2 and NIH3T3 cells was less than 80% (Figure 2). Compared with DP, 
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DS showed slightly greater viability. The non-degradable PEI is known to induce significant 
cytotoxic side effects. The strategy of preparing high-molecular-weight polycations from low-
molecular-weight oligocations via biodegradable disulfide linkages is beneficial in reducing 
toxicity. After inclusion of the HA and HA-SS-COOH envelope, an increase in the ratio of 
envelope to DNA significantly increased the viability of B16F10, HepG2 and NIH3T3 cells to 
the level of blank cells. The high viability (> 80%) indicates that DSS and DSH did not have 
significant toxicity at the working concentrations.   
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Figure 3. In vitro luciferase expression of different gene carriers in B16F10 (A, B), HepG2 
(C, D) and NIH3T3 (E, F) cells. (n = 6, *p < 0.05 by two-way ANOVA, followed by Tukey's 
post-hoc test). (DNA concentration is 2 μg/mL. For Fig. 3 A, C, and E, DP: PEI/DNA = 1.33; 
DS: OEI-SSx/DNA = 10; DSH: OEI-SSx/DNA = 10, HA/DNA = 0.2 ~ 2; DSS: OEI-
SSx/DNA = 10, HA-SS-COOH/DNA = 0.2 ~ 2; w/w. For Fig. 3 B, D, and F, DPH: PEI/DNA 
= 1.33, HA/DNA = 1; DPS: PEI/DNA = 1.33, HA-SS-COOH/DNA = 1; DSH: OEI-
SSx/DNA = 10, HA/DNA = 1; DSS: OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 2; w/w.)  
 
2.3. In Vitro Transfection  
The superiority with respect to gene transfection of the multi-responsive "turn-on" DSS was 
evaluated in NIH3T3 (CD44 negative[22]), HepG2 (CD44 positive[23]) and B16F10 (CD44 
positive[24]) cells (Figure 3). The gene expression level of the DS was much stronger than that 
offered by DP in both B16F10 and HepG2 cells. Different weight ratios of the HA-SS-COOH 
envelope to DNA in the range from 0.2 to 2 have successfully improved the transfection 
efficiency. In serum-free medium and 10% serum conditions, among them, DSS (the weight 
ratios of OEI-SSx and HA-SS-COOH to DNA were 10 and 2, respectively) was the  best with 
approximately 57-fold and 267-fold greater transfer rates than the DP group in HepG2 cells, 
respectively (Figure 3C and D, p < 0.05). Compared to the stable DSH envelope, which has 
the same OEI-SSx/DNA polyplexes core, multi-responsive "turn-on" DSS nanocarriers 
showed significantly greater luciferase levels (p < 0.05). Similar results can be yielded from 
the B16F10 cell line (Figure 3A and B) but not in HA receptor-negative NIH3T3 cells 
(Figure 3E and F).  
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Figure 4. GFP reporter gene expression of gene carriers at their optimized weight ratios on 
B16F10 cells. (A) Fluorescence images (Row 1) and bright field (Row 2, magnification 50 ×). 
(B) GFP-positive cells (%) were determined by flow cytometry. (DNA concentration is 2 
μg/mL. DP: PEI/DNA = 1.33; DS: OEI-SSx/DNA = 10; DSH: OEI-SSx/DNA = 10, HA/DNA 
= 1; DSS: OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 2; w/w) 
 
To further verify the potential of DSS for gene delivery, transfection with a GFP reporter gene 
was conducted in B16F10 and NIH3T3 cells. Fluorescent microscopy revealed the GFP-
transfected cells with bright green fluorescent spots (Figure 4A). Flow cytometry analysis 
was conducted to determine the percentage of transfected cells, and results similar to the 
microscopy were obtained (Figure 4B). Strikingly, the DSS group (71.4% GFP-positive cells) 
showed the strongest green fluorescence in B16F10 cells, indicating that DSS were beneficial 
for introducing exogenous genes into tumor cells. However, the improvement of DSS-
mediated transfection was not observed in CD44-negative NIH3T3 cells (Figure S4), which 
corresponds to the luciferase expression results. Moreover, through the visual inspection of 
cell morphology and density from the bright-field images, the DSH and DSS groups resulted 
in healthy B16F10 cells with a greater cell density. After being transfected with DP and DS, 
numerous cells detached from the culture plate and the cell density decreased. These 
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observations demonstrated that DSS and DSH did not have significant toxicity at the working 
concentrations.  
 
Figure 5. Cellular uptake of Cy5-labeled gene carriers (red) after incubation with cells using 
medium supplemented with serum for 4 hours. (A) B16F10, (B) HepG2, and (C) pretreatment 
of HepG2 cells with free HA. FITC-phalloidin (green) and DAPI (blue) were used to stain F-
actin and cell nuclei, respectively. Scale bars are 25 μm. (DP: PEI/DNA = 1.33; DS: OEI-
SSx/DNA = 10; DSH: OEI-SSx/DNA = 10, HA/DNA = 1; DSS: OEI-SSx/DNA = 10, HA-SS-
COOH/DNA = 2; w/w) 
 
2.4. Cellular Uptake and Intracellular Trafficking  
The uptake profile of DSS was assessed using CLSM (Figure 5A and B). After the cells were 
incubated with different gene carriers in the medium supplemented with 10% FBS for 4 hours, 
Cy5-labeled DSS and DSH nanocarriers were efficiently internalized into tumor cells 
(B16F10 and HepG2). Much stronger red pixels were observed inside cells compared with 
cells incubated with DP or DS. More importantly, no obvious differences could be found 
between cells incubated with DSH and DSS. Previous findings suggested that modification of 
HA with a certain number of disulfide linkages cannot influence CD44-mediated 
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endocytosis[25]. Because PEI/DNA nanocarriers were engulfed by the cells mainly through 
macropinocytosis[4b, 26], a free HA competition assay was used to further confirm the 
hypothesis about receptor-mediated endocytosis of HA derivative-coated nanocarriers on cells 
overexpressing CD44. Cells were pretreated with an excess amount of free HA and were then 
incubated with DSS and DSH. As shown in Figure 5C, free HA significantly inhibited the 
cellular uptake of DSS and DSH; however, the uptake of DS and DP in HepG2 cells was not 
reduced by pretreating with free HA. The above results reveal the feasibility of HA-mediated 
internalization of DSS into cancer cells overexpressing CD44.  
 
Figure 6. Confocal laser scanning microscope observation of intracellular delivery of DP, DS, 
DSH and DSS nanocarriers in HepG2 cells at different times. The nanocarriers were prepared 
with FITC-labeled OEI-SSx or PEI (green) and Cy5-labeled DNA (red). LysoTracker (blue) 
was used to stain the acidic late endosomes and lysosomes. 1: Cy5 channel; 2: LysoTracker 
channel; 3: overlay of 1 (Cy5), 2 (LysoTracker) and FITC channel. White arrows signify the 
coincidence of the endosomes/lysosomes and the nanocarriers. Yellow arrows indicate the 
nanocarriers escaping from the endosomes/lysosomes into the cytoplasm. White circles 
indicate the position of the nuclei. Red arrows show released DNA and suggest entry into the 
nucleus. Scale bar =10 μm. (DP: PEI/DNA = 1.33; DS: OEI-SSx/DNA = 10; DSH: OEI-
SSx/DNA = 10, HA/DNA = 1; DSS: OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 2; w/w) 
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For PEI/DNA polyplexes, the prime approach of uptake is macropinocytosis, while CD44 
receptor-mediated endocytosis is also involved for DSH and DSS nanocarriers. Because 
macropinocytosis is the endocytic pathway that is advantageous in endosomal escape, 
receptor-mediated endocytosis always results in lysosomal degradation.[26] Hence, the 
intracellular trafficking of the nanocarriers was observed by CLSM using Cy5-labeled DNA 
(red), FITC-labeled polycations (green), and LysoTracker (blue) marked late 
endosomes/lysosomes. As shown in Figure 6, after one hour of incubation, strong white 
pixels could be observed in DP, DS, and DSH as well as DSS-treated cells, which were 
generated from the colocalization of the yellow fluorescence nanocarriers with the blue 
endosome/lysosome dyes. No fluorescence pixels were ever detected in the nuclei, but rather, 
rare, red fluorescence pixels of the DS group were detected in the nuclei. Four hours later, 
part of the DSH was still sequestered in the endosomes/lysosomes, as reflected by the strong 
white pixels, whereas most of the yellow DSS dots were separated from the blue LysoTracker 
as in the DP and DS groups. It is noteworthy that the strong fluorescence signals from the DS 
and DSS groups detected in the nuclear regions were mainly detected as red fluorescence. We 
therefore concluded that DNA was in a decondensed form and successfully escaped from the 
endosomes.  
 
Figure 7. (A) Intracellular visualization of FRET between Cy3 and Cy5 dual-labeled DNA 
nanocarriers (DP, DSS and DPH) in HepG2 cells at different times. Red: signal of FRET Cy5; 
Green: Cy3 signal; Yellow: the merged signal of FRET Cy5 and Cy3. Scale bars are 10 μm. 
(B) Visualization of FRET Cy5 signal by confocal software (n=6, ** p < 0.05 by one-way 
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ANOVA, followed by Tukey's post-hoc test). (DP: PEI/DNA = 1.33; DSS: OEI-SSx/DNA = 
10, HA-SS-COOH/DNA = 2; DPH: PEI/DNA = 1.33, HA/DNA = 1; w/w) 
 
2.5. The Stimulus Unpacking of DSS Nanocarriers  
It is highly advantageous to employ a FRET technique to illustrate the dynamics of nucleic 
acids in the delivery process.[8d, 27] FRET imaging was performed to further validate whether 
the multi-responsive "turn-on" design was beneficial for stimulus unpacking of DSS and 
decondensation of DNA. HepG2 cells were incubated with DSS, DPH and DP generated from 
Cy5 and Cy3 dual-labeled DNA. To distinguish the Cy3 signal from the FRET-mediated Cy5, 
the Cy3 signal was pseudocolored green. After a 30-min incubation, we observed several 
yellow clusters in the DSS, DPH and DP groups (Figure 7A), indicating that the red FRET-
mediated Cy5 fluorescence mainly overlapped the green Cy3 fluorescence, suggesting a tight 
package status of carriers and nucleic acids at the early transfection stage. Even after three 
hours of incubation, many yellow clusters were still observed in both the DP and DPH groups 
coming from the strong FRET-mediated Cy5 signal co-localized with the Cy3 signal, which 
demonstrated the package status of the DNA/PEI core and the condensation form of DNA. 
Whereas little red signal could be detected in the DSS groups, a considerable amount of green 
fluorescence was expected to be distributed in the cytosol and nuclei. Compared to the DP 
and DPH groups, the value of the FRET-mediated Cy5 signal for the DSS was obviously 
decreased (p < 0.05, Figure 7B), revealing that the DNA was mainly shown to have an 
unpacking status at the late transfection stage and the consequent inability to excite Cy5. All 
of the data above demonstrate that the DNA in multi-responsive "turn-on" design DSS could 
maintain a stable package status at the early transfection stage, whereas the decondensed 
DNA was ready to transport into nuclei at the late transfection stage. 
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Figure 8. (A) NIRF images of the tumor-bearing nude mice after systemic administration of 
Cy5.5-labeled gene carriers. Arrows signify the tumor locations. (B) NIRF images of tissues 
dissected from the mice 6 hours post-administration. (DP: PEI/DNA = 1.33; DSS: OEI-
SSx/DNA = 10, HA-SS-COOH/DNA = 2; w/w) 
 
2.6. In Vivo Distribution 
In vivo biodistribution and tumor accumulation profiles of the DSS were further monitored 
using a CRi Maestro EX 3.0 NIRF imaging system. DP or DSS were generated from 50 μg of 
the Cy5.5-labeled plasmid administered intravenously into HepG2 tumor-bearing nude mice, 
and the NIRF images were taken at 1 and 6 hours. As illustrated in Figure 8A, the fluorescent 
signals of the DP group could be detected around the liver, tumor and spleen. Among them, 
the liver showed the strongest fluorescent signal. However, it was interesting to note that 
strong signal strength from the DSS-treated mice was detected in the liver and tumor one hour 
post-injection, followed by a gradual enhancement in the signal strength six hours post-
injection. Because the tumor sites still showed the strongest fluorescence 6 hours post-
injection, it was easy to distinguish tumors from other tissues (liver and spleen). The signal of 
tissues dissected from the mice was also detected (Figure 8B). The strongest signal from the 
DSS-treated mice was in the tumor site rather than the liver or the spleen indicating that the 
DSS had excellent tumor accumulation ability.  
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Figure 9. Luciferase activity in the tumors and organs of nude mice after (A) intratumoral and 
(B) intravenous injection with different gene formulations containing 50 μg pCMV-Luc. (n=6, 
** p < 0.05 by one-way ANOVA, followed by Tukey's post-hoc test) (C) Gene expression in 
tibialis anterior muscle of BALB/c mice after intramuscular injection of different gene 
formulations containing 10 μg pORF-LacZ.  
 
 
2.7. In Vivo Gene Transfection 
Encouraged by the excellent tumor accumulation performance of the multi-responsive "turn-
on" design DSS, in vivo gene delivery of DSS was further investigated in tumor-bearing nude 
mice. Different nanocarriers containing luciferase-encoding plasmid DNA (pCMV-luc) were 
injected intratumorally, and the luciferase expression in the main tissues was analyzed 2 days 
post-injection (Figure 9A). DPH and DPS with the stable PEI/DNA polyplexes core were 
used as controls for comparison with DSH and DSS, respectively. As expected, DSS showed 
the strongest transfection efficacy in the tumor and achieved 3.4 × 106 RLU mg-1 protein. It 
was approximately 90- and 25-fold stronger than the expression level of the golden standard 
DP and DPH groups, respectively (p < 0.05). Compared with DPS, which has the same 
detachable HA-SS-COOH envelope, DSS exhibited an almost 10-fold stronger transfection 
efficiency (p < 0.05). DSS was also superior to the DSH group with the same degradable OEI-
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SSx/DNA core (p < 0.05). This result indicated that DSS with the degradable OEI-SSx/DNA 
core and detachable and targeted HA-SS-COOH envelope resulted in significantly improved 
transfection in the tumor and reduced gene transfection in normal tissues via intratumoral 
administration.  
 
To investigate the potential of DSS for transfecting the hepatoma after intravenous injection, 
luciferase expression was evaluated in the same tumor model. As revealed in Figure 9B, 
luciferase expression was found in the tumor and other tissues, whereas luciferase expression 
in the heart and kidneys was minimal. The transfection efficiencies in the tumor were much 
stronger than in other normal organs. Nanocarriers with an HA or HA-SS-COOH envelope 
could introduce exogenous DNA to the tumor and achieve gene transfection, and the 
expression level was approximately 200-fold stronger than that obtained in other tissues (liver, 
spleen or lungs). Among the different gene nanocarriers, DSS achieved the best gene delivery 
performance showing a dramatic increase of approximately 70-fold over the DP group in the 
tumor while reducing gene expression in the spleen. Interestingly, the gene expression in the 
DSS and DP groups in the tumor was 16.6- and 2.5-fold greater than in the spleen, 
respectively. This demonstrates the superiority of DSS in the transfection of tumor tissue.  
 
Intramuscular administration is a promising strategy for gene therapy[28]. In this study, 
intramuscular gene transfection can not only serve as a model to evaluate the effect of gene 
release and nuclear transport on gene transfection, but also provide an intuitionistic way to 
investigate the toxicity of DSS in tissue. We carried out gene transfection studies using the 
LacZ gene via intramuscular injection. Dark blue domains distinctly appeared in the muscular 
tissue because of the β-galactosidase expression. As shown in Figure 9C, a large number of 
β-galactosidase-positive myofibers were obtained in the DSS-treated muscles. However, a 
few blue β-galactosidase-positive myofibers were found in the DP-treated muscles. Hardly 
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any blue myofibers were detected in the naked DNA and PBS-treated muscles. A comparison 
of gene transfer properties of DP and DSS indicated a higher efficiency of DSS in muscles. 
DP clearly did not have nuclear import capacity and showed inefficient transfection in non-
dividing skeletal muscle where there is no nuclear envelope breakdown.[29] Thus, transport 
across the nuclear membrane for muscle cells is a predominant hurdle to non-viral carriers.[30] 
Since skeletal muscles are CD44 negative and non-dividing,[31] enhancing gene release and 
nuclear transport of DSS contribute reasonably to successful transgene expression. Moreover, 
it was interestingly noted that DSS never displayed any detectable inflammation in muscles, 
whereas severe inflammation was found in the DP-treated muscles. This result could be 
reasonably ascribed to highly efficient dissociation of the DSS polyplexes and a detachable 
HA-SS-COOH coating to DNA/OEI-SSx inner polyplexes via electrostatic forces. 
 
3. Discussion 
Systemic gene delivery is a complicated and multistep process involving numerous biological 
barriers. Despite substantial efforts devoted to developing various gene carriers for 
conquering one or several impediments. Exploiting multifunctional carriers that can combatall 
of the obstacles simultaneously is a formidable challenge. In this study, the multi-responsive 
"turn-on" DSS nanocarriers (Scheme 1) can respond to the alterations in hyaluronidases and 
GSH at both the tumor site and the intracellular milieu. This design enabled DSS to remain 
stable during circulation and to effectively accumulate at the tumor site via systemic 
administration. Once internalized into the tumor cells by CD44 receptor-mediated endocytosis, 
the HA-SS-COOH envelope could be degraded stepwise by hyaluronidases at both the tumor 
site and the intracellular milieu. The nanocarriers further responded to a high concentration of 
GSH by completely detaching the envelope and disassembling the DNA-encapsulating core. 
These actions contribute to the endosomal escape and gene release functions to greatly 
  
20 
 
enhance nuclear gene delivery. DSS was capable of overcoming multiple transfection barriers 
that nanocarriers encounter upon systemic administration.  
 
To determine the multi-responsive "turn-on" process of the HA-SS-COOH envelope 
degradation and detachment as well as the OEI-SSx/DNA inner core dissociation, we 
measured the changes in the nanocarriers treated with a reductive agent and/or hyaluronidase 
with respect to the zeta potential, size and morphology. DSS, as it has a well-defined particle 
size (164.5 ± 6.7 nm) and zeta potential (15.5 ± 0.6 mV), was selected. After incubation with 
hyaluronidase, the size of the DSS increased. Whereas irregular and aggregated morphology 
could be observed in the DSS group after further treating with a reductive agent, the zeta 
potential decreased as well. These observations are most likely due to the collapse of the HA-
SS-COOH envelope by hyaluronidase and the breakdown of disulfide linkages in the 
envelope as well as the OEI-SSx. At the same time, the small pieces of OEI generated from 
the dissociation of the inner OEI-SSx/DNA core cannot effectively condense the nucleic acid, 
which is beneficial for on-demand gene release.  
 
Stable and effective nanocarriers through the self-assembly of DNA and polycations typically 
have a positive surface charge, which, however, can lead to undesirable side effects. Anionic 
natural polysaccharide hyaluronic acid derivatives serving as the envelope may reduce the 
non-specific electrostatic association with the cell membrane. In addition, the disulfide 
crosslinking of OEI-SSx is also beneficial for improving the cell viability of the gene 
nanocarriers. The potential for gene transfection evaluated using CD44-positive and -negative 
cells showed that the transfection activities of DSS were increased in CD44-positive cells 
(HepG2 and B16F10) compared with the DP control group. However, the extremely opposite 
effects on HA receptor-deficient NIH3T3 cells led to a lower gene expression. The effect of 
the bioresponsive detachable HA-SS-COOH envelope was critical and resulted in CD44 
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receptor-mediated endocytosis and exposing the OEI-SSx/DNA core for endosomal escape. 
The core was further disassembled by intracellular GSH leading to the release of DNA and 
the achievement of high transfection as well as low cytotoxicity. The bottleneck for gene 
delivery is to achieve balance between the protection and release of DNA. Therefore, this 
procedure is quite beneficial in improving transfection efficiency.  
 
A preliminary investigation of the contribution of the HA and HA-SS-COOH envelope for the 
uptake of nanocarriers showed that the uptake efficiency of DSS and DSH was improved in 
CD44-overexpressing cells and can be effectively inhibited by free HA. However, free HA 
competition did not influence the uptake of DP. The observations above imply that although 
the greater positive zeta potential of the DP and DS facilitated the electrostatic interaction 
between the nanocarriers and the negatively charged cell membranes, the biological 
recognition and affinity proved much more powerful for uptake[5]. This fast accumulation 
profile is a key factor for in vivo application because the contact between target cells and 
nanocarriers is typically transient in vivo[32]. Furthermore, the zeta potential of DSS was 15.5 
± 0.6 mV, revealing that a certain amount of envelope (envelope/DNA = 1, w/w) covered the 
surface of the OEI-SSx/DNA inner core but still could not shield all of the positive charge. 
One of the possibilities was that some OEI-SSx head groups were still evident on the surface 
even after envelope formation, and these groups may have led to macropinocytosis. Therefore, 
CD44 receptor-mediated endocytosis and macropinocytosis are the main methods for the 
uptake of DSS. HA derivatives enveloping nanocarriers were concluded to become 
internalized via macropinocytosis in CD44-negative cells based on the transfection results 
showing that the luciferase expression of HA derivatives enveloping the nanocarriers did not 
decrease drastically in NIH3T3 cells.  
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Not only internalization but also intracellular trafficking remain formidable obstacles for 
cancer gene therapy. A further evaluation of DSS for intracellular trafficking in living HepG2 
cells has been performed. After being taken up, both DP and DS were able to escape 
efficiently from endosomes because macropinocytosis always results in endosomal escape [26]. 
Successful endosome escape was also achieved by DSS in HepG2 cells, whereas some DSH 
was still sequestered in the endosomes/lysosomes, and both of these were taken up via 
macropinocytosis as well as through a receptor-mediated pathway. This was mainly ascribed 
to the fact that DSS with a detachable envelope could successfully activate the endosomal 
escape ability of OEI-SSx. Notably, DNA from both the DS and DSS groups was detected in 
an unpacking form, which could be primarily attributed to the timely dissociation of DSS and 
release of the genes by intracellular GSH. The decondensation behavior of DNA inside cells 
is a key determining factor for improving the gene transfer rate. FRET was also conducted to 
further validate that the multi-responsive "turn-on" design concept is useful for stimulus 
unpacking of DSS and decondensation of DNA.  
 
Although some gene carriers can achieve wonderful gene transfection in vitro, the in vivo 
performance has been proven to be unsatisfactory primarily due to the stability issue of 
nanocarriers and the presence of the mononuclear phagocyte system (MPS). The MPS 
consists of dendritic cells, blood monocytes, granulocytes, and tissue-resident macrophages in 
the liver and spleen that are responsible for clearing, processing, and degrading foreign 
materials.[33] In vivo biodistribution has shown that the fluorescent signals of the DP group 
could be detected around the liver, spleen and tumor. The fluorescent signals from the liver 
and spleen were much stronger than the signals from other tissues, which might be due to the 
positive surface charge (+27 mV) of DP. When the cationic DP nanocarriers interacted with 
the blood components, the delivered DP appears mainly in the liver and spleen. Recognized as 
exogenous objects, DP nanocarriers were readily cleared from systemic circulation by MPS in 
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the liver and spleen precluding accumulation in tumor cells. The strongest signal from the 
DSS group could be detected in the tumor tissue at the 6-hour time point, which emphasizes 
the favorable tumor accumulation profile of DSS. This result could be assigned to the 
enhanced permeability and retention effect and the targeting ability of HA-SS-COOH-coated 
nanocarriers to recognize receptors on HepG2 cells. This result could also be attributed to the 
fact that anionic HA-SS-COOH enveloped DSS had reduced plasma protein adsorption and a 
low rate of nonspecific cellular uptake. Fluorescence signals from the DSS group could be 
detected in the liver site because the liver sinusoidal endothelial cells have abundant HARE 
receptors[34]. Although the fluorescence signal of DP in the spleen was much stronger than the 
DSS signal at the 6-hour time point after injection, the gene expression of DP in the spleen 
was much lower than the DSS group 2 days after intravenous administration. Previous studies 
have demonstrated that the high gene transfection of cationic lipid–protamine–DNA (LPD) 
complexes can be obtained in the spleen 6 h after systemic administration but drop very 
rapidly thereafter.[35] Because the gene expression in the spleen drops very rapidly, the 
discrepancy between the biodistribution and the gene expression was probably due to the 
difference in the detection time. For intravenous administrations, the paramount obstacle for 
in vivo targeted gene delivery is the undesired interactions between gene carriers and blood 
components or non-target cells. Together, these results qualify multi-responsive "turn-on" 
design DSS as a promising gene delivery system for collectively conquering multiple 
biological hurdles that nanocarriers encounter upon intravenous administration.  
 
4. Conclusions 
In conclusion, we have developed multi-responsive "turn-on" DSS nanocarriers consisting of 
a hyaluronidase and GSH dual-sensitive HA-SS-COOH envelope and a bioreducible 
DNA/OEI-SSx inner core for combating biological barriers in non-viral gene delivery. DSS 
can respond to the alterations in hyaluronidases and GSH at both the tumor site and the 
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intracellular milieu.  The multi-responsive "turn-on" design enabled DSS to remain stable 
during circulation and effectively accumulate at the tumor site via systemic administration. 
Once internalized into the tumor cells by CD44 receptor-mediated endocytosis, the HA-SS-
COOH envelope could be degraded stepwise by hyaluronidases at both the tumor site and the 
intracellular milieu and could further respond to high concentration GSH by completely 
detaching the envelope and disassembling the DNA-encapsulating core. These multi-
responsive features are beneficial for facilitating endosomal escape and unpacking the loaded 
genes for nuclear delivery. DSS was systematically investigated in vitro and in vivo and was 
compared with some well-chosen control groups including the insensitive golden standard 
DNA/PEI (DP), non-enveloping DNA/OEI-SSx (DS) and stable envelope DNA/OEI-SSx/HA 
(DSH). These results revealed that the tumor accumulation ability, internalization and 
endosome escape of the DSS nanocarriers, DNA unpacking and nuclear transportation in 
serum-containing conditions were all remarkably improved by the multi-responsive "turn-on" 
design, resulting in enormously efficient gene transfection in vitro and in vivo. 
 
5. Experimental Section 
Chemicals and Reagents: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
hydroxybenzotriazole (HOBt) and cysteine hydrochloride were from Sinopharm. Hyaluronic 
acid (HA, MW 1600 KDa) was ordered from Aladdin. 3-Mercaptopropionic acid, 
dithiothreitol (DTT), branched polyethyleneimine 25 kDa (PEI), 3,3’-
disulfanediyldipropanoic acid (DSDPA), oligoethylenimine 800 Da (OEI), and 
hyaluronidases, as well as antibiotics (streptomycin and penicillin) were from Sigma-Aldrich. 
4',6-Diamidino-2-phenylindole (blue, DAPI) and FITC-labeled phalloidin (green) were 
obtained from Aldrich. The nucleic acid labeling kit Label IT® Cy3™ and Cy5™ were 
purchased from Mirus. LysoTracker DND-22 (Blue) was from Invitrogen. Fetal bovine serum 
(FBS) and Dulbecco’s modified Eagle’s medium (DMEM) were commercially available from 
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Life Technologies Corporation. The human hepatoma cells HepG2, mouse fibroblast cells 
NIH3T3 and murine melanoma cells B16F10 were purchased from Shanghai Institutes for 
Biological Sciences. pGL3 plasmid encoding luciferase and pEGFP plasmid encoding green 
fluorescent protein were purified with an EndoFree plasmid kit from Qiagen. The pCMV-Luc 
plasmid was constructed by cloning the luciferase gene from the pGL3 promoter vector into 
pcDNA 3.1 and then purifying. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was commercially available from Amresco. A BCA Protein Assay Kit and 
luciferase reporter gene assay kit were obtained from Pierce and Promega, respectively. The 
preparation of HBG buffer (2-[4-(2-hydroxyethyl)-1-piperazinyl] ethanesulphonic acid 
(HEPES) 20 mM, pH 7.4, 5% glucose) and other buffer solutions was achieved with MilliQ 
ultrapure water; the rest of the reagents were obtained from Aldrich and used directly.  
 
De Novo Synthesis of OEI-SSx and HA-SS-COOH: The OEI-SSx and HA-SS-COOH were 
synthesized as in our previous description.[6a, 36] Briefly, the carboxyl groups of 3,3'-
disulfanediyldipropanoic acid (DSDPA) were activated using NHS/EDC. The obtained active 
ester was dissolved in DMSO and mixed with an appropriate amount of OEI (the proportion 
of OEI and active ester was 1:1.2) under nitrogen for 48 hours. Pure OEI-SSx product was 
obtained after dialysis (MW cut-off: 7 kDa) and lyophilization. According to the gel 
permeation chromatography (GPC) analysis, the MW of OEI-SSx was comparable to PEI 25 
kDa.  
 
HA with a 30% (molar ratio) disulfide modification between the pendant carboxyl group and 
the backbone was performed as follows. The viscosity average molecular weight (Mv) of the 
degraded HA after purification and acid degradation was 409 kDa. The pendant carboxyl acid 
moieties of the HA were reacted with cystamine dihydrochloride by activation with HOBt and 
EDC at a molecular ratio of 3:1. Then, the disulfide bonds in the cystamine functionalized HA 
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were cleaved using an excess amount of DTT resulting in the free thiol group modified HA 
(HA-SH). Subsequently, the obtained HA-SH was further reacted with excess 3-
mercaptopropionic acid at 25 °C in a PBS buffer solution for 24 hours. After a thorough 
dialysis and freeze-drying, HA-SS-COOH with a 30% molar ratio of carboxyl groups 
modified with disulfide linkages was obtained. The Ellman's assay[37] and 1H NMR were 
conducted to monitor the products. 
 
Preparation of DSS Nanocarriers: OEI-SSx, HA-SS-COOH, HA and DNA were separately 
dissolved in HBG buffer. The OEI-SSx solution was then added to the DNA solution at a 
fixed concentration (100 ng μL-1) to generate DNA/OEI-SSx (DS) binary polyplexes at a 
weight ratio of 10. The DS polyplexes were maintained for 20 min at room temperature, and 
then the DS polyplexes were added to the HA-SS-COOH solution at HA-SS-COOH/DNA 
ratios ranging from 0.2 to 5, creating DNA/OEI-SSx/HA-SS-COOH (DSS) ternary polyplexes. 
DNA/OEI-SSx/HA (DSH) ternary polyplexes were fabricated as above. Unless otherwise 
specified, most DSS nanocarriers used in experiments were prepared at an envelope to DNA 
ratio of two. 
 
Stability of DSS in the Presence of GSH and Hyaluronidase: To evaluate the stability of the 
DSS in the reductive environment and in the presence of hyaluronidase, the DSS nanocarriers 
were evaluated using dynamic light scattering (DLS) and transmission electron microscopy 
(TEM). The nanocarriers with 3 μg mL-1 DNA were prepared and incubated with 10 mM DTT 
for 30 min at 37°C prior to estimating the size distribution and zeta potential. At the same 
time, the particle size changes of the DSS nanocarriers (the weight ratios of OEI-SSx and HA-
SS-COOH to DNA were 10 and 2, respectively) incubated with different concentrations of 
hyaluronidase (0, 60 and 120 unit mL-1) in acetate buffer (pH 5.5, 37°C) were recorded every 
20 min. In addition, changes in the DSS nanoparticle morphology were investigated by TEM 
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(Tecnai G2 F20 S-TWIN, FEI Company) after treatment with hyaluronidase (120 units mL-1) 
and/or DTT (10 mM) for 30 min at 37 °C. Untreated DSH (the weight ratios of OEI-SSx and 
HA to DNA were 10 and 2, respectively) and DSS were used as controls. 
 
Cell Culture and Cytotoxicity Assay: Cells were propagated to confluence in DMEM-HG 
medium supplemented with 10% FBS and penicillin-streptomycin. Cells were cultured at 
37°C in a humidified atmosphere of 5% carbon dioxide and were harvested with 0.25% 
trypsin and 0.03% EDTA. The cell viability with various nanocarriers was evaluated using the 
MTT assay. DP (the weight ratio of PEI to DNA was 1.33), DS (the weight ratio of OEI-SSx 
to DNA was 10), DSS and DSH nanocarriers with different HA-SS-COOH or HA to DNA 
weight ratios were added to reach 200 ng DNA in each well. After 1 day, 10 μL of the MTT 
solution (5 mg mL-1) was added to each well. After another four-hour incubation, 150 µL of 
DMSO was used to dissolve the formazan crystal. The cytotoxicity of the nanocarriers was 
detected using a microplate reader (Bio-Rad) at 560 nm. 
 
In Vitro Transfection: The gene transfer properties of the multi-responsive "turn-on" DSS 
nanocarriers were investigated using HepG2 (CD44-positive), B16F10 (CD44-positive) and 
NIH3T3 (CD44-negative) cell lines, respectively. For the luciferase assay, 1×104 cells per 
well were seeded in 96-well plates in 100 μL DMEM containing 10% FBS. The nanocarriers 
(weight ratios of nanocarriers: DP (PEI/DNA = 1.33), DS (OEI-SSx/DNA = 10), DSH (OEI-
SSx/DNA = 10, HA/DNA = 1), DSS (OEI-SSx/DNA = 10, HA-SS-COOH/DNA = 2), DPH 
(PEI/DNA = 1.33, HA/DNA = 1), DPS (PEI/DNA = 1.33, HA-SS-COOH/DNA = 1)) were 
added at the indicated OEI-SSx/DNA (10) and HA-SS-COOH or HA to DNA (0.2~5) ratios at 
a pGL3 plasmid concentration of 200 ng well-1 either with or without 10% FBS. After 4 hours 
of incubation, the transfection medium was replaced with fresh medium and incubated for an 
additional day. Then, the transfected cells were harvested, washed and lysed. A microplate 
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reader was used to measure the luciferase activity and normalized to milligrams of protein, 
and the average and standard deviation from triplicate transfections were determined.  
 
For the pEGFP transfection experiments, 3×105 B16 and NIH3T3 cells were seeded in 6-well 
plates in 2 mL DMEM containing 10% FBS. DSS nanocarriers of OEI-SSx/DNA =10 and 
HA-SS-COOH/DNA = 2 were selected to compact with pEGFP. DP, DS, DSH and DSS 
nanocarriers were added to 2 μg of the pEGFP-C1 plasmid per well without FBS. After 4 
hours of transfection, the medium was replaced with fresh medium and incubated for an 
additional 2 days. An inverted fluorescence microscope was used to evaluate the GFP-
positive cells. To quantitatively determine the GFP transfection efficiency, pEGFP-
transfected cells were washed twice with PBS (pH 7.4), harvested using trypsin, and washed 
again with PBS containing 3% serum; then, the cells were resuspended in PBS for FACS 
analysis.  
Uptake and Intracellular Trafficking: The molecular targeting ability of the DSS nanocarriers 
was evaluated using a confocal laser scanning microscope. Briefly, 2 × 104 HepG2 and B16 
cells were seeded in 35-mm confocal dishes (Φ=15 mm), and 30% Cy5-labeled DNA 
nanocarriers were added to the cells containing 300 ng DNA per well with 10% serum, 
followed by four hours of incubation. At the same time, competitive binding of CD44 
receptors between the HA-envelope nanocarriers and an excess amount of free HA was 
performed in HepG2 cells. After pretreatment with 0.2% w/v free HA for 1.5 hours, the 
HepG2 cells were incubated with different gene carriers in medium containing 10% FBS for 
an additional 4 hours. The cells were then washed twice with PBS (pH 7.4) and fixed with 4% 
formaldehyde. DAPI (blue, 5 μg mL-1) and FITC-labeled phalloidin (green, 1 μg mL-1) were 
used to stain cell nuclei and the actin cytoskeleton, respectively. Then, 5 mM HEPES 
containing 20 U/ml of heparin sodium was used to wash cells to remove the gene carriers that 
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attach to the cell surface. The intracellular localization of DNA carriers was observed using 
CLSM (Leica TCS SP5) in which the fluorescent probes of DAPI, FITC and Cy5 were 
excited at 364 nm, 495 nm and 633 nm, respectively. 
 
Moreover, the endosomal/lysosomal escape and nuclear localization of various nanocarriers 
(DP, DS, DSH and DSS) were also observed using CLSM. HepG2 cells were incubated with 
gene carriers prepared with Cy5-labeled DNA and FITC-labeled polycations for the indicated 
time intervals. Then, the lysosomes were stained with 75 nM LysoTracker Blue at 37°C for 
30 min. To thoroughly remove the gene carriers bound on the cell surface before confocal 
observation, a HEPES solution containing heparin sodium was used to wash cells to remove 
the nanocarriers attached to the cell surface. Fluorescent LysoTracker Blue probe, FITC and 
Cy5 were excited at 373 nm, 495 nm and 633 nm, respectively. 
 
Fluorescence Resonance Energy Transfer Technique: Fluorescence resonance energy transfer 
(FRET) imaging was carried out to study the package status and stimulus-responsive release 
of DNA from DSS nanocarriers in the reduced milieu. To monitor the FRET phenomenon, 
Cy5 and Cy3 dual-labeled plasmids were used to generate DP, DPH and DSS nanocarriers. 
The average fluorescent dye densities were 1 dye per 380 plasmid base pairs. Then, 2×104 
HepG2 cells were seeded in a confocal dish. DP, DPH and DSS nanocarriers were added to 
the cells containing 200 ng DNA per well with serum. After incubation for the indicated time 
intervals, the medium was removed. The gene carriers that attach to the cell surface were 
removed by washing with HEPES solution containing heparin sodium. The stimulus 
unpacking of the indicated gene carriers and decondensation behavior of the DNA were 
acquired using CLSM. The emission signals of Cy3 and FRET-Cy5 were observed in the Cy3 
(dichroic mirror 565-620 nm) and Cy5 (dichroic mirror 655-755 nm) channels, respectively, 
through excitation with a 543-nm laser. 
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In Vivo Real-Time Biodistribution: All animal experiments were conducted following the 
ethics of Sichuan University and the NIH guidelines for research animals. BALB/c nude mice 
were from the National Rodent Laboratory Animal Resources and were maintained under 
specific pathogen-free (SPF) conditions. A 50-µl aliquot of sterile physiological saline 
containing 106 HepG2 cells was subcutaneously injected into the axillary of five-week-old 
male mice (25 ± 3 g). When the volume (0.5 × major axis × minor axis 2) of the hepatoma 
tumors achieved approximately 100 mm3, they were subjected to the biodistribution study. 
Non-envelope or HA-envelope nanocarriers generated from 50 μg of Cy5.5-labeled plasmids 
were injected intravenously into mice. PBS saline was used as control. Biodistribution and 
tumor accumulation profiles were investigated using a CRi Maestro EX 3.0 near infrared 
fluorescence (NIRF) imaging system. At 6 h post-intravenous injection, the mouse organs and 
tumors were removed. Fluorescence signals for the Cy5.5-labeled nanocarriers in the 
dissected tissues were detected. The results were analyzed using the CRI Maestro 
measurement software. 
 
In Vivo Gene Transfection: Mice with a tumor volume of approximately 100 mm3 were 
randomly divided into 7 groups of 6 mice per group. For intratumoral injection transfection, 
naked DNA, DP, DPH, DPS, DSH, or DSS formulations containing 15 μg of pCMV-Luc 
were injected into the tumors. PBS saline was used as the blank control. For intravenous 
injection transfection, DP (the weight ratio of PEI to DNA was 0.8), DPH or DPS (the weight 
ratios of PEI and HA derivatives to DNA were 0.8 and 1, respectively), DS (the weight ratio 
of OEI-SSx to DNA was 6), DSH, or DSS (the weight ratios of OEI-SSx and HA derivatives 
to DNA were 6 and 1, respectively) formulations containing 50 μg pCMV-Luc were 
intravenously administered to mice. The mice were sacrificed after 2 days; the tissues were 
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resected and homogenized in lysis buffer. The supernatant was used to quantify the 
transfection efficiency after centrifugation. 
 
For intramuscular injection transfection, six-week-old male BALB/c mice were used to 
evaluate the gene transfection ability of DSS in muscle. To do this, 50 μl DNA, DS, DP, DSH 
or DSS formulations containing 10 μg pORF-LacZ were injected directly into the tibialis 
anterior muscles after removing the hair. PBS was used as the control. The muscles were 
harvested 72 h post-injection; the expression of β-galactosidase was evaluated using the 
Beyotime β-galactosidase reporter gene assay kit and photographed with a SONY camera. 
 
Statistical Analysis: All experiments used at least six independent samples, and each 
measurement was performed in triplicate. Data are reported as mean values ± standard 
deviation. *Significance in Figures 2 and 3 was determined using two-way ANOVA followed 
by Tukey's post hoc test. **Significance in Figures 1, 7 and 9 was evaluated using one-way 
ANOVA followed by Tukey's post-hoc test. All analyses were performed with SPSS 19.0 for 
Windows. P < 0.05 was considered statistically significant.  
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and then to activate endosomal escape and gene release mechanisms, resulting in efficient 
gene transfection. 
 
Keywords: gene delivery, nanocarriers, multi-responsive, site-specific, biological barriers 
Title: Multi-responsive “turn-on” nanocarriers for efficient site-specific gene delivery in 
vitro and in vivo  
 
Yiyan He1, Jie Zhou1, Shengnan Ma1, Yu Nie1, Dong Yue1, Qian Jiang1, Aisha Roshan 
Mohamed Wali2, James Zhenggui Tang2, Zhongwei Gu1*  
 
 
ToC figure  
 
 
 
 
  
35 
 
 
 
Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2013. 
 
Supporting Information  
 
 
Multi-responsive “turn-on” nanocarriers for efficient site-specific gene delivery in vitro 
and in vivo  
 
Yiyan He1, Jie Zhou1, Shengnan Ma1, Yu Nie1, Dong Yue1, Qian Jiang1, Aisha Roshan 
Mohamed Wali2, James Zhenggui Tang2, Zhongwei Gu1*  
 
1 National Engineering Research Center for Biomaterials, Sichuan University, 29 Wangjiang 
Road, Chengdu 610064, P. R. China. *E-mail: zwgu@scu.edu.cn & zwgu1006@hotmail.com 
(Prof. Zhongwei Gu); Fax: +86-28-85410653.  
 
2 Faculty of Science and Engineering, School of Pharmacy, University of Wolverhampton, 
Wulfruna Street, Wolverhampton WV1 1SB, UK 
 
 
Keywords: gene delivery, nanocarriers, multi-responsive, site-specific, biological barriers 
  
36 
 
 
 
Figure S1. Schematic preparation and molecular structure of (A) the disulfide-conjugated 
oligoethylenimine (OEI-SSx) and (B) the disulfide bond modified HA (HA-SS-COOH). 
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Figure S2. (A) GPC diagrams of OEI800Da, OEI-SSx (with and without DTT treatment) and 
PEI25kDa. (B) 
1H-NMR Spectrum of the disulfide bond modified HA (HA-SS-COOH) in D2O. 
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Figure S3. Concentration-dependent cytotoxicity of PEI25kDa, OEI800Da and OEI-SSx on 
HepG2 cells for 24 h of incubation (n=6, ** p < 0.05 by one-way ANOVA, followed by 
Tukey's post-hoc test).  
 
 
 
Figure S4. GFP reporter gene expression of gene carriers at their optimized weight ratios on 
NIH3T3 cells (scale bar = 500 μm).  
 
 
